An interventional study of Acupuncture in Breast Neoplasms, sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.
Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 527th largest by planned enrollment of the 1,520 interventional ones that give a count, is one of 187 that started in 2026, is one of 327 with no phase, reaches primary completion later than 901 of the 1,064 other live ones, and was the 1,925th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
Guangdong Provincial People's Hospital · Sites in China
Ages 18–75 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,930 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 279 · Phase 2 641 · Phase 3 371 · Phase 4 51
First in 1997; this study’s year is marked. 187 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 216 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,520 interventional studies, 241 across the 408 observational. Of the 446 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
488 of 1,930 have an industry lead sponsor. The 10 most frequent:
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine is the lead sponsor of 16 studies on the registry; 12 are open to participants now.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine has 4 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
248 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 248 to your calendar (.ics) → With an account.
Among the 1,930 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the effect-implementation mixed research design was adopted. The patients were assigned to the intervention group and the control group at a ratio of 2 : 1 by the central stratified randomization method. The stratification factors were four phenotypes of psychosomatic symptoms ( anxiety and depression, sleep disorders, fatigue and mixed symptoms ). The intervention group was determined by the three-stage conversation model of doctor-patient joint decision-making, and the personalized acupuncture intervention program was determined. Combined with the patient 's own needs and service accessibility, the hospital intervention subgroup or the medical-social-home intervention subgroup scenario was determined. The control group was given routine nursing. Because the intervention requires informed interaction between doctors and patients, only outcome evaluators and data analysts are blinded. The intervention period was 8 weeks of treatment and 4 weeks of follow-up, a total of 12 weeks. Based on the evaluation of the effect of acupuncture intervention on the improvement of psychosomatic symptoms, the study was guided by the CFIR framework to evaluate the implementation of the hospital intervention subgroup and the medical-social-family intervention subgroup formed after the joint decision-making of doctors and patients, identify the implementation obstacles and promotion factors, and evaluate the implementation outcomes such as acceptability, feasibility, implementation loyalty and coverage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one psychosomatic symptom meeting the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive personalized acupuncture intervention (acupuncture and/or auricular acupressure) determined through the Shared Decision Making three-stage conversation model, on top of standard care. Patients choose either hospital-based or hospital-community-family intervention sub-group based on personal needs and service accessibility. Treatment duration: 8 weeks intervention + 4 weeks follow-up.
Participants receive standard care only, including diet, exercise, emotional regulation guidance, and health education based on the Breast Cancer Psychosomatic Health Education Manual. No active acupuncture intervention for psychosomatic symptoms during the study period.
Acupuncture treatment can include acupuncture and auricular point sticking. Those who choose the acupuncture scheme, complete the treatment according to the acupuncture prescription, frequency and course of treatment stipulated in this scheme ; for those who choose the auricular point sticking scheme, the sticking, replacement and daily pressing are completed according to the provisions of this scheme ; those who chose the combined scheme received acupuncture and auricular point sticking at the same time. No matter which plan was selected, the hospital intervention subgroup and the medical-social-family intervention subgroup all performed the same treatment objectives, prescription principles, course of treatment and safety requirements.
Functional Assessment of Cancer Therapy-Breast, FACT-B
Instruments for assessing Quality of Life (QoL) among breast cancer patients;Functional Assessment of Cancer Therapy-Breast (FACT-B Version 4.0) Uniform response options: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much Unified scoring rule for all subscales and total scores: Higher scores indicate better quality of life among breast cancer patients; lower scores reflect more severe physical, emotional, social and breast-specific distress.
Time frame: 8 weeks
Hospital anxiety and depression scale,HADS
Hospital Anxiety and Depression Scale (HADS) Full Scoring Standard Specifications Subscale 1: Anxiety subscale (HADS-A) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe anxiety symptoms. Subscale 2: Depression subscale (HADS-D) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe depressive symptoms. HADS total score Composition: HADS-A score + HADS-D score Minimum score: 0 Maximum score: 42 Interpretation: Higher total scores indicate more severe combined anxiety and depression symptoms. Supplementary Response Option Rule (Standard HADS 4-point Likert) All items adopt 4-point scoring from 0 to 3; higher single item scores stand for worse emotional conditions.
Time frame: 8 weeks
Pittsburgh sleep quality index,PSQI
Pittsburgh Sleep Quality Index (PSQI) Full Scoring Standard Description PSQI component subscores (7 sleep dimensions) Each component score range: 0-3 PSQI global total score Full name: Pittsburgh Sleep Quality Index Global Score Minimum score: 0 Maximum score: 21 Interpretation: Higher global scores represent worse overall sleep quality; lower scores indicate better sleep quality.
Time frame: 8 weeks
Brief Fatigue Inventory,BFI
Brief Fatigue Inventory (BFI) Full Scoring Standard Description Single item scoring range for each fatigue item: 0-10 BFI Global Fatigue Severity Score Full name: Brief Fatigue Inventory Global Fatigue Severity Score Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe fatigue; lower scores represent milder fatigue status. Supplement The total global score is the average of all 9 items of the BFI. Each item uses a 0-10 numerical rating scale, where 0 = no fatigue at all and 10 = worst fatigue imaginable.
Time frame: 8 weeks
Brief Pain Inventory,BPI
Brief Pain Inventory (BPI) Full Scoring Standard Description Single item scoring range: Each pain-related item is scored on a 0-10 numeric rating scale (0 = no pain, 10 = worst pain imaginable) BPI Pain Severity Score Full name: Brief Pain Inventory Pain Severity Score Composition: Average score of 4 pain severity items (worst pain, least pain, average pain, pain right now) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores mean greater pain severity BPI Pain Interference Score Full name: Brief Pain Inventory Pain Interference Score Composition: Average score of 7 pain interference items (interference with general activity, mood, walking ability, normal work, relations with others, sleep, enjoyment of life) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe interference of pain on daily life
Time frame: 8 weeks
Acceptability of the intervention
Acceptability of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater acceptability. A total score of ≥16 indicates good acceptability.
Time frame: 8 weeks
Feasibility of the intervention
Feasibility of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater feasibility. A total score of ≥16 indicates good feasibility.
Time frame: 8 weeks
Implementation Fidelity: Auricular Acupressure Treatment Adherence Rate
Auricular acupressure treatment adherence rate = (Number of auricular acupressure sessions actually completed / Number of required sessions) × 100%. An adherence rate of ≥80% indicates good adherence.
Time frame: 8 weeks
Implementation Fidelity: Self-Pressing Adherence Rate
Self-pressing adherence was assessed by recording the daily frequency of self-pressing in patient logs and verifying the records by asking participants during follow-up visits. An adherence rate of ≥90% indicates good adherence.
Time frame: 8 weeks
Coverage of the intervention
Coverage was defined as the proportion of eligible breast cancer patients with psychosomatic symptoms who participated in the study.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
Of 2,664 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 26 months is below that.
Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine